{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:55:43Z","timestamp":1760622943032},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,9,11]],"date-time":"2014-09-11T00:00:00Z","timestamp":1410393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s12032-014-0232-0","type":"journal-article","created":{"date-parts":[[2014,9,10]],"date-time":"2014-09-10T05:52:52Z","timestamp":1410328372000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The clinicopathological characteristics with long-term outcomes in malignant mesothelioma"],"prefix":"10.1007","volume":"31","author":[{"given":"Mutlu","family":"Dogan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gungor","family":"Utkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cemil","family":"Hocazade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dogan","family":"Uncu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serife","family":"Toptas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuriye","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurullah","family":"Zengin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fikri","family":"Icli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,11]]},"reference":[{"key":"232_CR1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","volume":"113","author":"JE Herndon","year":"1998","unstructured":"Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723\u201331.","journal-title":"Chest"},{"key":"232_CR2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/annonc\/mdi094","volume":"16","author":"JP Steele","year":"2005","unstructured":"Steele JP, Klabatsa A. Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol. 2005;16:345\u201351.","journal-title":"Ann Oncol"},{"key":"232_CR3","first-page":"891","volume":"20","author":"S Emri","year":"2000","unstructured":"Emri S, Kocagoz T, Olut A, G\u00fcngen Y, Muti L, Baris YI. Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey. Anticancer Res. 2000;20:891\u20134.","journal-title":"Anticancer Res"},{"key":"232_CR4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/1096-9098(200009)75:1<55::AID-JSO10>3.0.CO;2-D","volume":"75","author":"D Piazza","year":"2000","unstructured":"Piazza D, Caruso F, Scaringi S, Ferrara M, Latteri F, Dell\u2019Erba D. Primary diffuse malignant peritoneal mesothelioma: case report and update of therapy. J Surg Oncol. 2000;75:55\u20138.","journal-title":"J Surg Oncol"},{"key":"232_CR5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1378\/chest.102.3.790","volume":"102","author":"T Sel\u00e7uk","year":"1992","unstructured":"Sel\u00e7uk T, C\u00f6pl\u00fc L, Emri S, Kalyoncu AF, Sahin AA, Baris YI. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest. 1992;102:790\u20136.","journal-title":"Chest"},{"key":"232_CR6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11864-001-0044-2","volume":"2","author":"BW Loggie","year":"2001","unstructured":"Loggie BW. Malignant peritoneal mesothelioma. Curr Treat Options Oncol. 2001;2:395\u20139.","journal-title":"Curr Treat Options Oncol"},{"key":"232_CR7","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1158\/0008-5472.CAN-05-4642","volume":"66","author":"AU Dogan","year":"2006","unstructured":"Dogan AU, Baris YI, Dogan M, Emri S, Steele I, Elmishad AG, Carbone M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 2006;66:5063\u20138.","journal-title":"Cancer Res"},{"key":"232_CR8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.thorsurg.2004.06.011","volume":"14","author":"L Zellos","year":"2004","unstructured":"Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin. 2004;14:469\u201377.","journal-title":"Thorac Surg Clin"},{"key":"232_CR9","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1007\/s12032-012-0276-y","volume":"29","author":"ET Elkiran","year":"2012","unstructured":"Elkiran ET, Kaplan MA, Sevinc A, et al. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. Med Oncol. 2012;29:3147\u201354.","journal-title":"Med Oncol"},{"key":"232_CR10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.7314\/APJCP.2013.14.1.249","volume":"14","author":"G Utkan","year":"2013","unstructured":"Utkan G, \u00dcr\u00fcn Y, Cangir AK, et al. Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups. Asian Pac J Cancer Prev. 2013;14:249\u201353.","journal-title":"Asian Pac J Cancer Prev"},{"key":"232_CR11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11864-008-0071-3","volume":"9","author":"HL Kindler","year":"2008","unstructured":"Kindler HL. Systemic treatments for mesothelioma: Standard and novel. Curr Treat Options Oncol. 2008;9:171\u20139.","journal-title":"Curr Treat Options Oncol"},{"key":"232_CR12","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","volume":"7","author":"VW Rusch","year":"2012","unstructured":"Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631\u20139.","journal-title":"J Thorac Oncol"},{"key":"232_CR13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1159\/000321370","volume":"80","author":"AC Tanrikulu","year":"2010","unstructured":"Tanrikulu AC, Abakay A, Kaplan MA, et al. A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration. 2010;80:480\u20137.","journal-title":"Respiration"},{"key":"232_CR14","first-page":"707","volume":"10","author":"KH Lee","year":"2009","unstructured":"Lee KH, Yoon HS, Choi SJ, et al. Asbestos exposure and malignant mesothelioma in Korea. Asian Pac J Cancer Prev. 2009;10:707\u201310.","journal-title":"Asian Pac J Cancer Prev"},{"key":"232_CR15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01243894-200605000-00004","volume":"1","author":"RM Flores","year":"2006","unstructured":"Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, Akhurst T, Rusch VW. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006;1:289\u201395.","journal-title":"J Thorac Oncol"},{"key":"232_CR16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00130404-200311000-00008","volume":"9","author":"A Ahamad","year":"2003","unstructured":"Ahamad A, Stevens CW, Smythe WR, Liao Z, Vaporciyan AA, Rice D, Walsh G, Guerrero T, Chang J, Bell B, Komaki R, Forster KM. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. 2003;9:476\u201384.","journal-title":"Cancer J"},{"issue":"21","key":"232_CR17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdq173","volume":"2010","author":"RA Stahel","year":"2010","unstructured":"Stahel RA, Weder W, Lievens Y, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;2010(21):126\u20138.","journal-title":"Ann Oncol"},{"key":"232_CR18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2010.04.004","volume":"78","author":"JP Meerbeeck van","year":"2011","unstructured":"van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol. 2011;78:92\u2013111.","journal-title":"Crit Rev Oncol Hematol"},{"key":"232_CR19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11864-011-0146-4","volume":"12","author":"MG Zauderer","year":"2011","unstructured":"Zauderer MG, Krug LM. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol. 2011;12:163\u201372.","journal-title":"Curr Treat Options Oncol"},{"key":"232_CR20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.lungcan.2006.04.014","volume":"53","author":"G Utkan","year":"2006","unstructured":"Utkan G, B\u00fcy\u00fck\u00e7elik A, Yal\u00e7in B, Akbulut H, Demirkazik A, Din\u00e7ol D, Onur H, G\u00f6ren D, Mousa U, Senler FC, I\u00e7li F. Divided dose of cisplatinum combined with gemcitabine in malignant mesothelioma. Lung Cancer. 2006;53:367\u201374.","journal-title":"Lung Cancer"},{"key":"232_CR21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11864-000-0047-4","volume":"1","author":"HL Kindler","year":"2000","unstructured":"Kindler HL. Malignant pleural mesothelioma. Curr Treat Options Oncol. 2000;1:313\u201326.","journal-title":"Curr Treat Options Oncol"},{"key":"232_CR22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.bjc.6600118","volume":"86","author":"JM Haarst van","year":"2002","unstructured":"van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ, van Meerbeeck JP. Multicenter phase II study of gemcitabine and cisplatinum in malignant pleural mesothelioma. Br J Cancer. 2002;86:342\u20135.","journal-title":"Br J Cancer"},{"key":"232_CR23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","volume":"17","author":"MJ Byrne","year":"1999","unstructured":"Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BW. Cisplatinum and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25\u201330.","journal-title":"J Clin Oncol"},{"key":"232_CR24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.bjc.6600505","volume":"87","author":"AK Nowak","year":"2002","unstructured":"Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicenter phase II study of cisplatinum and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491\u20136.","journal-title":"Br J Cancer"},{"key":"232_CR25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","volume":"64","author":"G Carteni","year":"2009","unstructured":"Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C, Stahel R. Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64:211\u20138.","journal-title":"Lung Cancer"},{"key":"232_CR26","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1378\/chest.08-2665","volume":"136","author":"M Ray","year":"2009","unstructured":"Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136:888\u201396.","journal-title":"Chest"},{"key":"232_CR27","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","volume":"27","author":"LM Krug","year":"2009","unstructured":"Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatinum followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007\u201313.","journal-title":"J Clin Oncol"},{"key":"232_CR28","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2004.10.071","volume":"22","author":"W Weder","year":"2004","unstructured":"Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel RA. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451\u20137.","journal-title":"J Clin Oncol"},{"key":"232_CR29","first-page":"3441","volume":"29","author":"M Ralli","year":"2009","unstructured":"Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K. Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res. 2009;29:3441\u20134.","journal-title":"Anticancer Res"},{"key":"232_CR30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/sonc.2002.30236","volume":"29","author":"PH Sugarbaker","year":"2002","unstructured":"Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, Ortega-Perez G, Stuart OA, Marchettini P, Yoo D. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol. 2002;29:51\u201361.","journal-title":"Semin Oncol"},{"key":"232_CR31","doi-asserted-by":"crossref","unstructured":"Krug LM, Wozniak AJ, Kindler HL, et al. Randomized phase II trial of pemetrexed\/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer 2014 Jul 5. doi: 10.1016\/j.lungcan.2014.06.008 . [Epub ahead of print].","DOI":"10.1016\/j.lungcan.2014.06.008"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0232-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-014-0232-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0232-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T21:03:48Z","timestamp":1565816628000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-014-0232-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,11]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["232"],"URL":"https:\/\/doi.org\/10.1007\/s12032-014-0232-0","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,11]]},"article-number":"232"}}